GGrantIndex
← Leaderboards

Tufts Medical Center

Boston, MA

Compare ↔
$729,341,520
Total funding
738
Grants

Funding over time

peak $54.3M · FY2005–25
$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$716,891,222 · 712
AHRQ$9,596,513 · 21
FDA$2,093,145 · 3
CDC$760,640 · 2

By mechanism

R01$420,384,678 · 261
U01$106,607,469 · 25
R21$31,002,727 · 76
T32$28,416,665 · 14
K23$21,801,256 · 35
P50$19,200,608 · 10

Investigators at Tufts Medical Center

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Jennifer Dupont$2,780,3671 gr2Amanda Ruth Vest$1,057,2171 gr3Lauren Alysse Biwer$498,0001 gr4Michael C. Hughes$396,9341 gr

Emerging Leaders

6–10 yrs in

1Krishna C Penumatsa$2,572,2051 gr2Pei-Jung Lin$2,475,0261 gr3Alysse Gail Wurcel$2,468,2005 gr4Paul Mathew$2,410,3631 gr5Raymond Luke Comenzo$1,901,9782 gr6Elena Byhoff$1,129,3371 gr7Jenica Upshaw$818,6251 gr8Benjamin Seth Wessler$659,4342 gr

All-Time

Most funded here, all years

1Linden T Hu$22,973,82521 gr2Iris Z Jaffe$17,096,6436 gr3Joel S Schuman$16,951,3772 gr4Michael G Shlipak$16,091,29412 gr5Wei Li$15,618,11514 gr6Athan Kuliopulos$15,203,9266 gr7Bradford A Navia$14,039,9362 gr8Pablo Argueso$13,174,6915 gr

Largest grants

Vitamin D and type 2 diabetes (D2d)$10,610,574
U01 · FY2014 · DK
Vitamin D and type 2 diabetes (D2d)$9,854,116
U01 · FY2013 · DK
Early EMS and ED Use of GIK for ACS: The IMMEDIATE Trial$9,273,477
U01 · FY2006 · HL
Early EMS and ED Use of GIK for ACS: The IMMEDIATE Trial$8,111,828
U01 · FY2005 · HL
Vitamin D and type 2 diabetes (D2d)$6,550,000
U01 · FY2015 · DK
Vitamin D and type 2 diabetes (D2d)$6,550,000
U01 · FY2016 · DK
Vitamin D and type 2 diabetes (D2d)$6,550,000
U01 · FY2017 · DK
Vitamin D and Type 2 Diabetes (D2d)$5,467,912
U01 · FY2018 · DK
Early EMS and ED Use of GIK for ACS: The IMMEDIATE Trial$4,444,879
U01 · FY2004 · HL
Remote Tai Chi for Knee Osteoarthritis: an Embedded Pragmatic Trial$4,132,197
UH3 · FY2025 · AT
Conversational Agent to Improve Guideline Concordant Care for People with Cervical Cancer Screening Abnormalities$3,277,279
R01 · FY2025 · CA
Covert Cerebrovascular Disease Detected by Artificial Intelligence (C2D2AI): A Platform for Pragmatic Evidence Generation for Stroke and Dementia Prevention$2,894,758
RF1 · FY2023 · NS
Improving Medical Decision Making for Older Patients with End Stage Renal Disease$2,311,041
R01 · FY2023 · AG
GENERAL CLINICAL RESEARCH CENTER$2,284,251
M01 · FY2005 · RR
Molecular Mechanisms of Vascular Relaxation$2,220,662
P01 · FY2004 · HL
Molecular Mechanisms of Vascular Relaxation$2,212,515
P01 · FY2006 · HL
GENERAL CLINICAL RESEARCH CENTER$2,204,914
M01 · FY2004 · RR
Molecular Mechanisms of Vascular Relaxation$2,204,586
P01 · FY2005 · HL
Molecular Mechanisms of Vascular Relaxation$2,179,138
P01 · FY2008 · HL
Molecular Mechanisms of Vascular Relaxation$2,164,038
P01 · FY2007 · HL